Gonadorelin

Gonadorelin (GnRH)

In simple words

Gonadorelin is an exact copy of a natural brain hormone that switches on the sex glands. Doctors use it to test the hormone system and to restore sperm production when the body's own hormones are lacking.

What this molecule is

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ — 10 aa decapeptide. Pyroglutamate at the N-terminus. Endogenous hypothalamic hormone.

Why it is studied

Natural regulator of the reproductive axis. Used in the diagnosis of hypogonadism (GnRH test) and in pulsatile pump therapy for hypogonadotropic hypogonadism. Meta-analysis of 41 studies, n=1673: spermatogenesis restored in 78% of patients. The pulsatile pump is more effective than gonadotropins.

How it works

Pulsatile binding to pituitary GnRH-R → ↑LH and FSH → gonadal activation: testosterone + spermatogenesis (men) / estradiol + ovulation (women). Key principle: pulses = stimulation, continuous administration = receptor desensitization = axis suppression.

Doses used in studies

In diagnostics, 100 mcg IV was used once (GnRH test), with LH measured at 0, 30, and 60 min. In pump therapy, 5–20 mcg SC every 90–120 min was used. Only under the supervision of an endocrinologist/reproductive specialist.

Combined with in studies

  • hCG — sequential or combined therapy in IHH
  • GnRH antagonists (cetrorelix) — NOT compatible
  • GnRH agonists (triptorelin) — NOT compatible — desensitization

Level of evidence

Level A Human clinical trials. There are randomized controlled trials (RCTs), or the compound has been approved by a regulatory agency. The most reliable level. Decades of clinical use, meta-analyses. Prescription drug.

Important to know

🔴 Prescription drug. Only as prescribed by an endocrinologist / reproductive specialist. Self-treatment is unacceptable.

Studies in PubMed

  1. Efficacy of Gonadotropin Treatment for Induction of Spermatogenesis in Men With Pathologic Gonadotropin Deficiency: A Meta-Analysis. (Clin Endocrinol (Oxf), 2025)
  2. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. (Am J Mens Health, 2019)
  3. Role of Gonadotropin-releasing Hormone Stimulation Test in Diagnosing Gonadotropin Deficiency in Both Males and Females with Delayed Puberty. (Chin Med J (Engl), 2015)
  4. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. (J Clin Endocrinol Metab, 2002)
  5. Induction of spermatogenesis and fertility in hypogonadotropic azoospermic men by intravenous pulsatile gonadotropin-releasing hormone (GnRH). (Gynecol Endocrinol, 1988)
  6. Spermatogenesis of Male Patients with Congenital Hypogonadotropic Hypogonadism Receiving Pulsatile Gonadotropin-Releasing Hormone Therapy Versus Gonadotropin Therapy: A Systematic Review and Meta-Analysis. (World J Mens Health, 2021)

Research peptides are laboratory reagents (Research Use Only). They are not medicines and are not intended for use in humans or animals.